Grajales Beltrán Ana Gabriela, Lytle Derek, Vojicic Jelena, Grover Prerna, Latifovic Lidija, Golden Shane, Ling Juejing, Millson Brad, Cane Alejandro
Vaccines Medical Affairs, Pfizer Canada, Kirkland, QC H9J 2M5, Canada.
Market Access, Pfizer Canada, Kirkland, QC H9J 2M5, Canada.
Vaccines (Basel). 2023 Mar 28;11(4):748. doi: 10.3390/vaccines11040748.
The burden of all-cause community-acquired pneumonia (CAP), including pneumococcal pneumonia, is typically estimated using ICD codes where pneumonia is coded as the most responsible diagnosis (MRDx). Pneumonia may also be coded as other than most responsible diagnosis (ODx) based on administrative and reimbursement criteria. Analyses including pneumonia as MRDx only likely underestimate hospitalized CAP incidence. The aim of this study was to estimate the burden of hospitalized all-cause CAP in Canada and to assess the contribution of ODx-coded cases to the overall disease burden. This longitudinal retrospective study obtained data from the Canadian Institutes of Health Information (CIHI) for adults 50+ years hospitalized for CAP between 1 April 2009 and 31 March 2019. Cases were identified as those where pneumonia was either diagnosis code type M (MRDx) or pre-admit comorbidity type 1 (ODx). Reported outcomes include pneumonia incidence rate, in-hospital mortality, hospital length of stay, and cost. Outcomes were stratified by age group, case coding, and comorbidity. Between 2009-2010 and 2018-2019, CAP incidence increased from 805.66 to 896.94 per 100,000. During this time, 55-58% of cases had pneumonia coded as ODx. Importantly, these cases had longer hospital stays, higher in-hospital mortality, and higher cost of hospitalization. The burden of CAP remains substantial and is significantly greater than that estimated by solely focusing on MRDx-coded cases. Our findings have implications for policy decision making related to current and future immunization programs.
包括肺炎球菌肺炎在内的所有原因引起的社区获得性肺炎(CAP)的负担,通常使用国际疾病分类(ICD)编码来估算,其中肺炎被编码为最主要诊断(MRDx)。根据行政和报销标准,肺炎也可能被编码为非最主要诊断(ODx)。仅将肺炎作为最主要诊断进行的分析可能会低估住院CAP的发病率。本研究的目的是估算加拿大住院全因CAP的负担,并评估ODx编码病例对总体疾病负担的贡献。这项纵向回顾性研究从加拿大卫生信息研究所(CIHI)获取了2009年4月1日至2019年3月31日期间因CAP住院的50岁及以上成年人的数据。病例被确定为肺炎诊断编码类型为M(MRDx)或入院前合并症类型为1(ODx)的患者。报告的结果包括肺炎发病率、住院死亡率、住院时间和费用。结果按年龄组、病例编码和合并症进行分层。在2009 - 2010年至2018 - 2019年期间,CAP发病率从每10万人805.66例增至896.94例。在此期间,55 - 58%的病例肺炎被编码为ODx。重要的是,这些病例的住院时间更长、住院死亡率更高且住院费用更高。CAP的负担仍然很大,且明显大于仅关注MRDx编码病例所估算的负担。我们的研究结果对当前和未来免疫规划的政策决策具有启示意义。